Skip to content
DataLookout
Menu

NCT07895498

A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

pustular drug eruption assessed
Timeframe: Day 56 ± 3 days

Arms and interventions

SOCP aloneActive comparator

Minocycline Face: Hypochlorous acid solution Face: Hydrocortisone Trunk: Triamcinolone Scalp: Clobetasol propionate Photoprotection: Broad-spectrum sunscreen

Ivermectin 200 mcg/kg orally weekly plus SOCPExperimental

Ivermectin 200mcg/kg orally weekly PLUS SOCP above as in Arm A

Drugs: Minocycline, Hypochlorous Acid, Hydrocortison cream, Triamcinolone (TAC) 0.1% cream, Clobetasol, Ivermectin

Other: Photoprotection

Sites

7 sites in 1 country